Working… Menu

Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease (HOPE4MCI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03486938
Recruitment Status : Recruiting
First Posted : April 3, 2018
Last Update Posted : July 2, 2019
National Institute on Aging (NIA)
Information provided by (Responsible Party):

Brief Summary:
The primary objective of the study is to evaluate the efficacy of AGB101 on slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with mild cognitive impairment due to Alzheimer's Disease (MCI due to AD) also known as prodromal AD. Participants will be randomized to receive placebo or AGB101 (220 mg), once daily for 78 weeks. Secondary objectives are to assess the effect of AGB101 compared with placebo on clinical progression as measured by Mini-Mental State Examination (MMSE) and Functional Activities Questionnaire (FAQ).

Condition or disease Intervention/treatment Phase
Mild Cognitive Impairment Prodromal Alzheimer's Disease Drug: Placebo Oral Tablet Drug: AGB101 220 mg tablet Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 830 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
Actual Study Start Date : January 15, 2019
Estimated Primary Completion Date : November 2021
Estimated Study Completion Date : November 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: Placebo Oral Tablet
Matching placebo to AGB101 tablet once daily, taken orally, for 78 weeks.
Drug: Placebo Oral Tablet
Placebo oral tablet

Experimental: AGB101 220 mg tablet
Single 220 mg AGB101 tablet once daily, taken orally, for 78 weeks.
Drug: AGB101 220 mg tablet
220 mg AGB101 active compound

Primary Outcome Measures :
  1. CDR-SB [ Time Frame: 78 weeks ]
    Change in CDR-SB score from baseline

Secondary Outcome Measures :
  1. MMSE [ Time Frame: 78 weeks ]
    Change in MMSE score from baseline

  2. FAQ [ Time Frame: 78 weeks ]
    Change in FAQ score from baseline

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   55 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subjects between 55 and 85 years old (inclusive) in good general health:

    1. Willing and able to consent and participate for the duration of the study
    2. Have eighth-grade education or good work history sufficient to exclude mental retardation
    3. Have visual and auditory acuity adequate for neuropsychological testing
    4. Have proficient fluency of the native local language to participate in all the neuropsychological test assessments
  2. Have a study partner who has sufficient contact with the subject to be able to provide assessment of memory changes, who can accompany the subject to all the clinic visits for the duration of each visit, and who is able to provide an independent evaluation of the subject's functioning
  3. Have MCI due to AD as defined by all of the following criteria and consistent with the National Institute on Aging-Alzheimer's Association criteria:

    1. MMSE scores between 24 and 30 (inclusive; exceptions may be made for subjects with <8 years of education at the discretion of the sponsor)
    2. A memory complaint reported by the subject or his/her study partner
    3. Evidence of lower memory performance based on delayed recall in the International Shopping List Test (ISLT)
    4. A clinical dementia rating (CDR) score of 0.5 with a memory box score of ≥0.5
    5. Essentially preserved activities of daily living
    6. Cognitive decline not primarily caused by vascular, traumatic, or medical problems (alternative causes of cognitive decline are ruled out)
  4. Permitted medications:

    1. With potential pro-cognitive effects, such as cholinesterase inhibitors and memantine, must be at a stable dose for ≥3 months prior to screening and remain stable throughout the study; estrogen replacement therapy, Ginkgo biloba, and vitamin E must be at a stable dose for ≥4 weeks prior to screening and remain stable throughout the study
    2. Other psychotropics, such as antidepressants and antipsychotics, must be at a stable dose for ≥3 months prior to screening and remain stable throughout the study
  5. Willing and able to undergo imaging procedures:

    1. A Positron Emission Tomography (PET) scan with Florbetaben(an 18F isotope diagnostic agent) or documented evidence of an amyloid positive PET scan.

      The Florbetaben scan performed at baseline must be read by a qualified physician with experience in reading amyloid PET scans, and it should be consistent with the presence of amyloid plaques.

    2. Repeated MRI scans (3 Tesla) with no contraindications to MRI. MRI scan results are consistent with the diagnosis of amnestic MCI due to Alzheimer's disease with no clinically significant findings of non-AD pathology that could account for the observed cognitive impairment.
  6. Willing to allow collection of blood for apolipoprotein E (ApoE) genotyping.

Exclusion Criteria:

  1. Use of anticonvulsant medications or excluded psychotropic medications within 3 months prior to the baseline visit
  2. Participation in a therapeutic clinical study for any medical or psychiatric indications within 3 months (6 months for biologics) of the screening visit, or at any time during the study.

    Subjects must understand that they may only enroll in this clinical study once; they may not enroll in any other clinical study while participating in the current study, and they may not participate in a clinical study of a drug, biologic, therapeutic device, or medical food, in which the last dose/administration was received within 3 months (6 months for biologics) prior to screening.

  3. History of hypersensitivity or lack of tolerability to AGB101 (levetiracetam)
  4. Severe renal impairment (creatinine clearance of <30 mL/minute) or undergoing hemodialysis
  5. Any significant neurological disease other than suspected incipient AD, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder (lifetime history; infant febrile seizures are not exclusionary), subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits, or known structural brain abnormalities
  6. Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body
  7. Diagnosis of major depression or bipolar disorder, as described in the Diagnostic and Statistical Manual of Mental Disorders, 5th Ed (DSM-5), within the past 3 years.

    Psychotic features, agitation, or behavioral problems within the last 3 months that could lead to difficulty complying with the protocol. Subjects must not have a major depressive disorder or other types of depression that could confound diagnosis of MCI due to AD, or clinical assessments, in the opinion of the investigator. The geriatric depression scale (long form score >9 suggests depression) results should be reviewed by the investigator to assist in this determination.

  8. Modified Hachinski Ischemic Scale (HIS) score >4
  9. History of schizophrenia (DSM-5 criteria)
  10. History of alcohol or substance abuse or dependence within the past 3 years (DSM-5 criteria)
  11. Any significant systemic illness or unstable medical condition that could lead to difficulty in complying with the protocol requirements.
  12. Clinically significant abnormalities in B12 or thyroid function test that might interfere with the study.

    A low B12 (below normative range for elderly) is exclusionary, unless follow-up labs (homocysteine and methylmalonic acid) indicate that it is not physiologically significant. If the B12 deficiency is treated, subjects may become eligible to participate in the study.

  13. Residence in a skilled nursing facility. Individuals in independent living communities, assisted living facilities, residential care facilities, or continuing care communities are eligible provided they engage in a sufficient spectrum of activity to permit assessment of all 6 domains contributing to the CDR-SB. Individuals in these facilities must also have a caregiver who has the ability to observe the subject during the study and can participate in clinical evaluations.
  14. Any use of excluded medications (e.g., antiepileptics, certain antidepressants or antipsychotics, antihistamines with anticholinergic properties, opiates)
  15. Participation in clinical studies using the ISLT, Behavioral Pattern Separation (BPS-O) task, or the trail making test (A, B) within 1 month of screening
  16. Female subjects must not be pregnant, lactating, or of childbearing potential (i.e., they must be 2 years post menopause or surgically sterile)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03486938

Layout table for location contacts
Contact: Clinical Development (610) 964-2000

Layout table for location information
United States, Arizona
Banner Alzheimer's Institute Recruiting
Phoenix, Arizona, United States, 85006
Contact: Po-Heng Tsai    602-839-6900   
Contact: Joshua Sipes    602 839 6924   
United States, California
Senior Clinical Trials, Inc. Not yet recruiting
Laguna Hills, California, United States, 92653
Contact: Robert Feldman    949-588-0909   
Contact: Mary Burt    949-588-0909   
Excell Research Inc Recruiting
Oceanside, California, United States, 92056
Contact: Sherry Soefje    760-758-2222   
Contact: Manos Manuel    760-758-2222   
Care Access Research, Santa Clarita Recruiting
Santa Clarita, California, United States, 91321
Contact: Surisham Dhillon    661-286-2360   
Contact: Shari Lim    661 286 2360   
United States, Colorado
The Mile High Research Center Recruiting
Denver, Colorado, United States, 80218
Contact: Jack Klapper    303-839-9900   
Contact: Amy K Greaves    303-839-9900   
United States, Florida
Brain Matters Research Recruiting
Delray Beach, Florida, United States, 33445
Contact: Mark Brody    561-374-8461   
Contact: Ana Scolari-Fuquay    561-374-8461   
MD Clinical Not yet recruiting
Hallandale Beach, Florida, United States, 33009
Contact: Beth Safirstein    954-455-5859   
Contact: Damaris Alonso    954-455-5757   
Bioclinica Research Recruiting
Melbourne, Florida, United States, 32940
Contact: Christopher Galloway    321-202-2712   
Contact: Deidra M Shubert    321-202-2712   
Miami Jewish Health Not yet recruiting
Miami, Florida, United States, 33137
Contact: Marc Agronin    305-762-1426   
Contact: Arlene Moreno    305-751-8626 ext 64108   
Bioclinica Research Not yet recruiting
Orlando, Florida, United States, 32806
Contact: Ira Goodman    407-426-9299   
Contact: Candice Montros    407 426 9299   
IMIC Research Recruiting
Palmetto Bay, Florida, United States, 33157
Contact: Evelyn Lopez-Brignoni    305-252-2199   
Contact: Minela Suljicic-Martinez    786-310-7477   
The Roskamp Institute, Inc Recruiting
Sarasota, Florida, United States, 34243
Contact: Andrew Keegan    941-256-8018   
Contact: Lois Davis    941-256-8018   
University of South Florida Psychiatry and Behavioral Neurosciences Recruiting
Tampa, Florida, United States, 33613
Contact: Jean Fils    813-974-2832   
Contact: Julie Samson    813-974-7006   
United States, Georgia, LLC Recruiting
Decatur, Georgia, United States, 30033
Contact: Marshall Nash    404-475-0552   
Contact: Nino Valishvili    404-475-0552   
United States, Illinois
Great Lakes Clinical Trials Recruiting
Chicago, Illinois, United States, 60640
Contact: Jeffrey Ross    773-275-3501   
Contact: Steve Satek    (773) 275-3500   
United States, Maryland
Johns Hopkins University School of Medicine Recruiting
Baltimore, Maryland, United States, 21205
Contact: Marilyn Albert    410-614-3040   
Contact: Carrie Speck    410-955-5057   
Sub-Investigator: Arnold Bakker         
United States, New Jersey
Global Medical Institutes LLC; Princeton Medical Institute Recruiting
Princeton, New Jersey, United States, 08540
Contact: Jeffrey Apter    609-921-3555 ext 20   
Contact: Claire Pasquale    609-921-3555 ext 15   
Neurology Specialist of Monmouth County, PA Recruiting
West Long Branch, New Jersey, United States, 07764
Contact: Noah Gilson    732-935-1857   
Contact: Avraham Tuvy    732 935 1857   
United States, New York
Neurological Associates of Albany PC Recruiting
Albany, New York, United States, 12208
Contact: Richard Holub    518-426-0575   
Contact: Jillian Ela    518-426-0575   
Richmond Behavioral Associates Not yet recruiting
Staten Island, New York, United States, 10312
Contact: Mark DiBuono    718-317-5522   
Contact: Deborah Arias    718-317-5522 ext 307   
United States, Ohio
Neuro-Behavioral Clinical Research, Inc Recruiting
North Canton, Ohio, United States, 44720
Contact: Shishuka Malhotra    330-493-1118   
Contact: Lisa K Boyce    330-493-1118   
United States, Texas
Clinical Trials of Texas, Inc Recruiting
San Antonio, Texas, United States, 78229
Contact: Jason Miller    210-949-0122   
Contact: Nathan Cortez    210 949 0122   
Canada, Ontario
Toronto Memory Program Not yet recruiting
Toronto, Ontario, Canada, M3B 2S7
Contact: Sharon Cohen    416-386-9761   
Contact: Mary Jane Bacolor    416-386-9761   
Sponsors and Collaborators
National Institute on Aging (NIA)
Layout table for investigator information
Principal Investigator: Richard Mohs, PhD AgeneBio
Study Director: Sharon Rosenzweig-Lipson, PhD AgeneBio

Layout table for additonal information
Responsible Party: AgeneBio Identifier: NCT03486938     History of Changes
Other Study ID Numbers: AGB101 MCD
R56AG055416 ( U.S. NIH Grant/Contract )
R01AG048349 ( U.S. NIH Grant/Contract )
R01AG061091 ( U.S. NIH Grant/Contract )
First Posted: April 3, 2018    Key Record Dates
Last Update Posted: July 2, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Cognitive Dysfunction
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cognition Disorders